Vascular-targeting agent

Vascular Disrupting Agents Markets, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Pharmaceutical, Health, Cardiology, Cancer treatments, Vascular-targeting agent, Cancer

The "Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions" report has been added to ResearchAndMarkets.com's offering.
  • The 'Vascular Disrupting Agents Market, 2021-2030 report features an extensive study of the current and future potential of vascular disrupting agents, being developed for the treatment of various types of cancer.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with vascular disrupting agents, over the next decade.
  • Detailed profiles of the prominent players in this domain (shortlisted on the basis of number of vascular disrupting agents in development pipeline).

Global Small Molecule Cancer Drug Market to 2026 - Drug Price, Dosage & Clinical Trials Insight - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Health, Pharmaceutical, Medicine, Clinical medicine, Cancer, Cancer treatments, Antineoplastic drugs, Chemotherapy, Occupational safety and health, Oncology, Treatment of cancer, Tyrosine kinase inhibitors, Birabresib, Vascular-targeting agent

The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years.
  • Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
    USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
    Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    An important parameter that should be associated with any of the cancer treatment is its specificity.
  • 3.2 Small Molecule Cancer Drug vs. Immunotherapy
    3.3 Small Molecule Cancer Drugs vs.